{"id":576952,"date":"2026-08-06T22:22:08","date_gmt":"2026-08-06T22:22:08","guid":{"rendered":"https:\/\/www.newsbeep.com\/il\/576952\/"},"modified":"2026-08-06T22:22:08","modified_gmt":"2026-08-06T22:22:08","slug":"daratumumab-induces-high-responses-despite-relapse-in-patients-with-ittp","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/il\/576952\/","title":{"rendered":"Daratumumab Induces High Responses Despite Relapse in Patients With iTTP"},"content":{"rendered":"<p>Daratumumab achieved rapid responses with manageable safety in patients with immune-mediated thrombotic thrombocytopenic purpura (iTTP), according to updated results of the international DarTTP study presented at the International Society on Thrombosis and Haemostasis 2026 Congress. However, some patients required additional treatment after relapse.<\/p>\n<p>The multicenter, retrospective study evaluated the safety and efficacy of daratumumab in 30 heavily pretreated adult patients from 13 European centers who were in the acute (n=5) or remission (n=25) phase. The patient population was largely male (78%), with a median age of 47 years. Patients were dosed across three treatment regimens: 1,800 mg subcutaneous (n=15), 16 mg\/kg intravenous (n=14), or 8 mg\/kg intravenous (n=1).<\/p>\n<p>The primary end point was ADAMTS13 remission, defined as more than 20% activity. Secondary end points were adverse events, time to response, ADAMTS13-relapse-free survival, and sustained response lasting more than 6 months.<\/p>\n<p>The response rate was 70% (21\/30) after a median of 3 weeks, with 14 complete responses and seven partial ADAMTS13 remissions. Of these patients, 67% (14\/21) had sustained responses. Notably, daratumumab\u2019s efficacy continued in key patient subgroups, including all patients (5\/5) with prior toxicities, 67% (12\/18) of patients who relapsed, and 57% (4\/7) of patients who were refractory to several drugs including rituximab. Younger age was associated with better responses to daratumumab; the median age of patients who responded was 43 years, compared with 54 years for those who did not respond (P=0.04).<\/p>\n<p>Despite these high response rates, relapses occurred in 40% of patients, including two clinical relapses and 10 ADAMTS13 relapses. However, six out of nine patients received successful retreatment, leading to longer remissions in two patients. The ADAMTS13-relapse-free survival was 11.8 months (95% CI, 7.1 months-not reached).<\/p>\n<p>Infusion-related reactions were mostly low-grade and were associated with the type of administration, occurring in 30% of patients overall, 53% of patients who received intravenous administration, and 7% of patients who received subcutaneous administration. The one patient death observed was considered unrelated to daratumumab.<\/p>\n<p>\u201cAlthough one-third of responses were short-lasting, retreatment was frequently effective, supporting consideration of maintenance strategies in selected patients,\u201d the authors wrote. \u201cDaratumumab may represent a valuable option for younger patients with a relapsing disease course or refractory\/intolerant to prior therapies.\u201d<\/p>\n","protected":false},"excerpt":{"rendered":"Daratumumab achieved rapid responses with manageable safety in patients with immune-mediated thrombotic thrombocytopenic purpura (iTTP), according to updated&hellip;\n","protected":false},"author":2,"featured_media":576953,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10],"tags":[163,85,46],"class_list":["post-576952","post","type-post","status-publish","format-standard","has-post-thumbnail","category-health","tag-health","tag-il","tag-israel"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts\/576952","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/comments?post=576952"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts\/576952\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/media\/576953"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/media?parent=576952"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/categories?post=576952"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/tags?post=576952"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}